Rallybio
About:
Rallybio is an biotechnological research and development services intended to transform the lives of patients with a devastating disease.
Website: http://rallybio.com/
Top Investors: F-Prime Capital, Connecticut Innovations, Viking Global Investors, The Rise Fund, Pivotal bioVenture Partners
Description:
Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise.
$239M
$10M to $50M
Farmington, Connecticut, United States
2018-01-01
Jeffrey Fryer, Martin Mackay, Stephen Uden
11-50
2024-04-10
Public
© 2025 bioDAO.ai